# Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

> **NCT00083382** · PHASE2 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 83 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pamidronate
- **DRUG:** Thalidomide
- **DRUG:** Zometa

## Key facts

- **NCT ID:** NCT00083382
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083382, "Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00083382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*